首页   按字顺浏览 期刊浏览 卷期浏览 Melphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexam...
Melphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexamethasone (VBAMDex) Therapy for Multiple Myeloma

 

作者: D. Peest,   H. Deicher,   R. Coldewey,   I.-M. v. Broen,   U. Cammerer,   R. Hein,   L. Hoffmann,   H. Konyar,   E.D. Kreuser,   J. Selbach,   H.J. Weh,  

 

期刊: Onkologie  （Karger Available online 1990）
卷期: Volume 13, issue 1  

页码: 43-44

 

ISSN:0378-584X

 

年代: 1990

 

DOI:10.1159/000216718

 

出版商: S. Karger GmbH

 

关键词: Multiple myeloma;Induction therapy

 

数据来源: Karger

 

摘要:

136 untreated multiple myeloma patients of stage II and III were collected in the study. 37/51 stage II patients had progressive disease and were treated with melphalan and prednisone (MP). 85 patients were of stage III and randomized into MP and vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) treatment groups. 55% of MP treated patients responded versus 75% of the VBAMDex group. Since the study has been activated only 16 months ago, no difference in survival could be observed.

 

点击下载:  PDF (824KB)



返 回